Drug Delivery

Up to now, drugs administered to patients suffering from osteoarthritis (OA) relieve pain but do not halt the progression of the disease itself. This is in part due to the challenge of developing the appropriate drug delivery strategies. We want to fill this void by combining disease-modifying OA drug candidates with the promising biomaterials developed in our lab. Our research is focused on 1) drug-loaded macroporous hydrogels that promote the closure of cartilage defects and 2) polymer chains targeting degraded collagen and conjugated with drugs delivered according to pre-designed controlled release profiles.